Renaissance Capital logo

ANRO News

Renaissance Capital's February IPO Market Update

Alto Neuroscience logo

In February, 10 IPOs raised a combined $2.0 billion, led by early debuts from a handful of $100+ million offerings. Deal flow was led by healthcare and senior facilities provider American Healthcare REIT (AHR) and Mexican discount grocer...read more

CNS disorder biotech Alto Neuroscience prices upsized IPO at $16, the high end of the range

Alto Neuroscience logo

Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, raised $129 million by offering 8 million shares at $16, the high end of the range of $14 to $16. The company offered 1.3 million more shares than...read more

CNS disorder biotech Alto Neuroscience sets terms for $101 million IPO

Alto Neuroscience logo

Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, announced terms for its IPO on Monday. The Los Altos, CA-based company plans to raise $101 million by offering 6.7 million shares at a price range of...read more

US IPO Week Ahead: Amer Sports tees up its $1.7 billion US IPO

AS

Updated Monday, 1/29. Five listings are currently scheduled for the week ahead, although other issuers may join the calendar throughout the week. Leading the pack, sports equipment and apparel maker Amer Sports (AS) plans to raise...read more